The opioid epidemic has fueled the transmission of HCV, particularly among younger persons, who are often unaware of their risks and prevented from receiving timely treatment due to a variety of care barriers, even in settings ideally suited to identifying and treating HCV.
The high cost of DAA-based regimens remains an ethical issue and an obstacle to treatment accessibility. Shorter treatment regimens may offer substantial cost savings, improved treatment adherence, and a reduced rate of side effects.
The information, posted to the Food and Drug Administration (FDA) website, states that both the Recombivax HB adult (10mcg/mL) and dialysis (40mcg/mL) formulations are not expected to be available in 2019.
Due to the limited amount of published literature analyzing treatment options for older chronic HCV infection patients, the study authors aimed to determine the efficacy and tolerability of glecaprevir/pibrentasvir in this population.
The Indication section has been revised to state that Viread is intended for use in the treatment of chronic hepatitis B in adults and pediatric patients 2 years of age and older weighing at least 10kg.